&w=3840&q=100)
US fertility rate reached new low in 2024 with 1.6 kids per woman: CDC
The US was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to World Bank data.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an executive order meant to expand access to and reduce costs of in vitro fertilisation and backing the idea of baby bonuses that might encourage more couples to have kids.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
We're seeing this as part of an ongoing process of fertility delay. We know that the US population is still growing, and we still have a natural increase more births than deaths, she said.
The US Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024.
In the early 1960s, the US total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
Worry is not a good moment to have kids, and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
The things that they are doing are really symbolic and not likely to budge things for real Americans, she said.
Increase in births in new data The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1 per cent increase in births about 33,000 more last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the US Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
News18
4 hours ago
- News18
What Is Alpha-gal Syndrome? The Tick-Borne Allergy Making Red Meat And Dairy Dangerous
Last Updated: Alpha-gal Syndrome from tick bites causes severe allergies to red meat and dairy, with symptoms like itching, hives, and anaphylaxis Red meat and dairy are common in diets around the world, but a rare and serious allergy is turning these everyday foods into potential health threats, all because of a tick bite. Alpha-gal Syndrome, triggered when a person is bitten by certain types of ticks, can cause the immune system to react violently to red meat and even dairy products. As a result, foods that were once safe can suddenly cause severe allergic reactions. The condition is gaining attention worldwide, with cases on the rise and awareness still worryingly low. Symptoms of Alpha-gal Syndrome can include itching, hives, stomach pain, nausea, and even anaphylaxis—a potentially life-threatening reaction. What makes it more difficult to detect is the delayed onset of symptoms, which often appear two to six hours after eating the food. Many patients mistake it for food poisoning or unrelated illness, leading to delayed diagnosis and prolonged suffering. What Is Alpha-gal Syndrome? Alpha-gal Syndrome isn't a typical food allergy. It stems from a sugar molecule called galactose-alpha-1,3-galactose—known simply as alpha-gal—which is found in the meat of mammals such as cows, pigs, and deer. After being bitten by certain types of ticks, including the lone star tick and the deer tick, a person's immune system can become sensitised to this molecule. Later, eating red meat or dairy can trigger a severe allergic response. The allergy is particularly tricky because symptoms don't appear immediately. The delayed reaction makes it harder to connect the dots between what someone ate and how they're feeling hours later. Reactions range from mild stomach issues to full-body hives and life-threatening anaphylaxis. According to the US Centres for Disease Control and Prevention (CDC), as many as 450,000 people in the United States alone may be affected by Alpha-gal Syndrome. Once thought to be restricted to the southeastern US, the allergy is now appearing in new areas—including internationally. Serbia recently reported its first confirmed case, according to local magazine Vreme. Currently, there is no cure. Treatment mainly involves avoiding all forms of red meat, dairy, and any food products with hidden animal-based ingredients. Preventing further tick bites is also critical, as each one can increase sensitivity and worsen the allergy. In some cases, the condition may ease over time, but this varies by individual. As scientists continue researching the condition, experts recommend staying vigilant—especially when spending time in tick-prone areas. For those experiencing unexplained reactions after meals, Alpha-gal Syndrome may be worth discussing with a medical professional. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
4 hours ago
- Mint
NIH Grant Cuts Arent Saving Money. Theyre Wasting It.
(Bloomberg Opinion) -- The Trump administration's waves of massive cuts to funding at the National Institutes of Health are framed as a recasting of research priorities and a way to save taxpayer money. Another way to frame it is an exercise in massive waste. In terminating nearly 750 NIH grants over the past two months, the government dumped years of investment down the drain. The unceremonious end to those projects means we won't know the answers to studies that intended to improve the health of Americans. According to a Bloomberg Opinion analysis(1), Health and Human Services data show that some $373 million had already been spent on the 242 discontinued R01 grants, an NIH award that is considered critical to launching a successful career. Researchers tend to get that chunk of funding — typically a sizable amount that supports their work for 3 to 5 years — after they've done a few years of preliminary work. It's all geared toward asking a big scientific question. Our analysis doesn't include the untold number of NIH grants at Harvard University affected by the administration's $2.2 billion federal funding freeze this week — a punishment for refusing to comply with the government's long list of demands. But even if those funds are eventually restored, the disruption risks derailing studies related to ALS, tuberculosis and many other health conditions. Funding was pulled just as some of these projects were getting off the ground, while others were rounding into their last year of funding — a point where enough data would finally be collected to offer concrete results. Our analysis found that nearly 40% of the canceled R01 grants supported research that had yet to produce findings, meaning all of the agency's prior investments won't benefit the public. Take, for example, the abrupt end to Washington University of St. Louis professor Jeremy Goldbach's five-year grant to test the first evidence-backed intervention intended to help teachers, administrators and social workers support LGBTQ youth. A little over three years in, Goldbach had collected a massive amount of data from 20 schools — thousands of students had participated. But without his last rounds of funding, he won't be able to track the program's efficacy at the last four schools needed for the results to be statistically meaningful. That's more than $2.1 million that NIH already spent on the project down the drain, all because the government pulled the last few hundred thousand. (Goldbach's grant was one of many caught up in a sweep of cuts related to President Trump's gender ideology executive order.) But the loss goes beyond that. Goldbach's project built off years of earlier work. Before getting to the point where a review panel of more than two dozen experts felt the concept was promising enough to merit a large-scale study, the researcher had to design and test it. That work was supported by two earlier awards from NIH and financial help from foundations, which together amounted to nearly $900,000 in investment in the project. Moreover, about 15 people's jobs are on the line between the loss of this funding and around seven other terminated grants for studies that Goldbach is a collaborator on. At the other end of the spectrum, Northwestern University professor Michelle Birkett's $3.8 million grant was ended in the first of its five years. The funding was awarded to understand —and ultimately address — disparities in HIV transmission and substance use among gay men and transgender women. Although only a fraction of that promised money had been spent, Birkett had invested years of work into designing and securing funding for the study and had already recruited a community board across each of the five cities where it was poised to launch. Countless stories of similarly needless waste — research interrupted midstream and sidelined careers— live behind the HHS's long list of canceled funding. That translates into a massive number of health insights the public simply won't know about — yet had already paid to support. So many of those unanswered questions centered on prevention: How can we encourage simple changes that could have a big impact on the physical and mental health of Americans — and ultimately save the health care system money? For example, a cluster of projects devoted to improving uptake of the HPV vaccine, which has stalled in recent years, was among the research that recently lost funding. Not enough adolescents are getting the shots despite a growing body of data showing its ability to prevent deaths from cervical cancer in women and potentially lower the rates of head and neck, anal, penile, vaginal and vulvar cancers. Some of those HPV vaccine studies were well underway but, as with Goldbach's project, had yet to enroll enough volunteers to yield meaningful data on how to convince people to get the shot. Ultimately, that doesn't just waste the taxpayer money already spent on those grants; it could also cost the health care system later, in the form of otherwise preventable cancer cases. Abandoning these projects is far from an exercise in efficiency, as the Trump administration likes to tout. A more accurate word to sum up what's happening with these cuts would be: nonsensical. More From Bloomberg Opinion: Want more Bloomberg Opinion? OPIN GO. Or subscribe to our daily newsletter. (1) Bloomberg Opinion analyzed 748 terminated NIH grants from the HHS TAGGS data as of April 16. We merged in additional information about each grant, including the project start date and the number of associated publications, from the NIH RePORTER database. The length of each study is the time between the project's beginning and the grant termination date, which we visualize for three of the most common award types: R01, U01 and U54 grants. The funding already spent on R01s is calculated from the 'total amount expended' field in the HHS data. This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. Carolyn Silverman is a data journalist for Bloomberg Opinion. She previously served as a data scientist for the University of Chicago Crime Lab and Education Lab. More stories like this are available on
